Bone grafts are implantable materials that promote bone healing through its osteoconductive, osteogenic, and osteoinductive mechanisms. The bone grafts are used in surgical procedures such as spinal fusion surgeries, bone replacement, ensuring new bone formation, and repair of bone fractures. Moreover, bone grafting has applications in the treatment of various bone related disorders such as congenital pseudoarthrosis, dental bone grafting problems, and complex fractures. Allografts, synthetic bone grafts, and demineralized bone matrix are the most commonly used bone grafts worldwide.

The global bone grafts & substitutes market was valued at $2,652.6 million in 2020, and is projected to reach $3,362.6 million by 2028, registering a CAGR of 4.3% from 2021 to 2028. Rise in incidences of musculoskeletal disorders, development of biocompatible synthetic bone grafts, technological advancements in medical field leading to a shift from autograft to allograft drive the growth of the bone grafts & substitutes market. For instance, as per the data published by World Health Organization (WHO), in 2021, musculoskeletal conditions are the prominent contributors to disability globally, with low back pain being the single primary cause of disability in 160 countries or early deaths. Low back pain causes the greatest burden with a prevalence of 568 million people and this trend is expected to continue for next few years.

In addition, increase in cases of lifestyle disorders such as diabetes and obesity add to the risk of developing degenerative joint diseases that further fuel the growth of the market. For instance, according to IDF Diabetes Atlas, Ninth Edition 2019, approximately 463 million adults had diabetes and by 2045, the number is estimated to increase to 700 million across the world. Apart from this, more than 1.1 million children were suffering from type 1 diabetes in 2019, which reveals the severity of this disease. Increase in incidences of diabetic cases leading to degenerative joint disorders is expected to provide high market growth and opportunities in near future. On the other hand, high cost of surgeries and ethical issues related with bone grafting procedures restrict the market growth. Conversely, emerging markets, rise in interests of key players toward R&D activities in bone grafts and its substitutes, and increase in demand for orthopedic procedures particularly in geriatric population are expected to provide profitable opportunities for the growth of the market in near future.

The research report categorizes the bone graft & substitute market based on product type, application, and region. By product type, it is classified into allografts, bone grafts substitutes, and cell-based matrices. The allografts are further categorized to machined allografts and demineralized bone matrix. The bone graft substitutes segment is further classified into bone morphogenic proteins (BMP) and synthetic bone grafts. By application, it is divided into spinal fusion, trauma, craniomaxilofacial, joint reconstruction, and dental bone grafting. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

This market has witnessed several product launches and approvals over the past few years. This is evident from the strategic launch of cryopreserved osteochondral allograft, ProChondrixCR by Stryker Corporate, in April 2018, while the NuVasive launched AttraX Scaffold Biologic an absorbent ceramic-collagen bone graft with an optimized surface, in June 2018. Key players profiled in this report include Arthrex, Inc., Baxter International Inc., Integra LifeSciences Holdings Corporation, Johnson & Johnson (DePuy Synthes), Medtronic Plc., Musculoskeletal Transplant Foundation, NuVasive, Inc., Stryker Corporation, Xtant Medical Holdings, Inc., Inc., and Zimmer Biomet Holdings, Inc.

KEY BENEFITS FOR STAKEHOLDERS

? The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
? The report provides a quantitative analysis for the period of 2021-2028 to enable stakeholders to capitalize on the prevailing market opportunities.
? Extensive analysis of the market based on products helps understand the type of devices used to treat musculoskeletal disorders and degenerative joints diseases.
? Competitive intelligence highlights the business practices followed by leading players across various regions.
? Comprehensive analysis of all geographic regions helps determine the prevailing opportunities in these regions.
? Key market players and their strategies are analysed to understand the competitive outlook of the overall market.
? Extensive analysis of the market is conducted by following key product positioning and monitoring the top contenders within the market framework.

KEY MARKET SEGMENTS
By Product
- Allografts
o Machined allografts
o Demineralized bone matrix
- Bone Grafts Substitutes
o Bone morphogenic proteins (BMP)
o Synthetic bone grafts
- Cell based matrices

By Application
- Spinal fusion
- Trauma
- Craniomaxillofacial
- Joint reconstruction
- Dental bone grafting
By Region
- North America
o U.S.
o Canada
o Mexico
- Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
- Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia-Pacific
- LAMEA
o Brazil
o South Africa
o Saudi Arabia
o Rest of LAMEA
KEY MARKET PLAYERS
- Arthrex, Inc.
- Baxter International Inc.
- Integra LifeSciences Holdings Corporation
- Johnson & Johnson ( DePuy Synthes )
- Medtronic Plc.
- Musculoskeletal Transplant Foundation
- NuVasive, Inc.
- Stryker Corporation
- Xtant Medical Holdings, Inc.
- Zimmer Biomet Holdings, Inc.